Authors
Fenna De Vries, Rob Ter Heine, Eric J F Franssen
Published in
Nederlands tijdschrift voor geneeskunde. Volume 70. Oct 07, 2026. Epub Oct 07, 2026.
Abstract
The shift from injectable to oral biologicals represents a significant leap in drug delivery, addressing patient hurdles such as needle phobia and treatment burden. Innovations such as the "robotic pill" and chemical enhancers have overcome gastrointestinal barriers, achieving sufficient bioavailability for therapeutic effects. However, this convenience poses substantial challenges.Pharmacologically, oral routes suffer from high variability and strict administration protocols, often leading to the early discontinuation of treatment. Environmentally, low absorption rates necessitate the massive overproduction of active ingredients, thereby increasing the ecological footprint. Economically, easy access may trigger an unsustainable surge in patient volume and evergreening practices that block cheaper alternatives.Thus while oral biologicals enhance patient comfort, they require a strategic re-evaluation of prescribing roles. Healthcare providers must balance individual convenience with the long-term sustainability, cost-effectiveness, and environmental integrity of the healthcare system.
PMID:
43055311
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0